Imagen de Portada

Efficacy of long‐term risankizumab treatment for moderate‐to‐severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks (LIMMitless trial)

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autores principales:	Bruce Strober, Hervé Bachelez, Jeffrey Crowley, Boni E. Elewski, Melinda Gooderham, Alan Menter, Robert Strohal, Michael M. Chen, Tianshuang Wu, Tianyu Zhan, Huzefa Photowala, April Armstrong
Formato:	Artículo Open Access
Publicado:	Wiley 2024
Materias:	Journal of the European Academy of Dermatology and Venereology
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Mission impossible? Caveats in interpreting and comparing long‐term efficacy in biologic studies for moderate‐to‐severe plaque psoriasis
por: Richard G. Langley, et al.
Publicado: (2025)

Pharmacokinetic‐pharmacodynamic modelling of risankizumab using chronic plaque psoriasis real‐world data
por: Charlotte M. Thomas, et al.
Publicado: (2026)

A novel nomogram to predict psoriatic arthritis in patients with plaque psoriasis
por: Minjia Tan, et al.
Publicado: (2024)

Real‐world effectiveness, drug survival and safety of risankizumab over a period of 2 years in 158 patients with moderate‐to‐severe plaque psoriasis
por: Natalia Rompoti, et al.
Publicado: (2024)

Effectiveness and safety of risankizumab dose optimization in adult patients with plaque psoriasis: An international multicentre retrospective cohort study
por: A. Bagit, et al.
Publicado: (2024)

Effectiveness of risankizumab for the treatment of psoriatic arthritis: a multicenter, real‐world study
por: Dario Graceffa, et al.
Publicado: (2024)

Dysregulation of epigenetic, biological and mitotic age in the context of biologic drug treatment and phototherapy in plaque psoriasis patients
por: Richie Jeremian, et al.
Publicado: (2024)

Effectiveness of ixekizumab for the treatment of moderate‐to‐severe plaque psoriasis with involvement of difficult‐to‐treat areas: A 52‐week multicenter retrospective study
por: Mario Valenti, et al.
Publicado: (2024)

Umbilical psoriasis is not relevant to psoriatic arthritis
por: Maki Takada, et al.
Publicado: (2024)

Efficacy and safety of risankizumab by baseline corticosteroid use and achievement of corticosteroid‐free clinical and endoscopic outcomes in patients with moderately to severely active Crohn's disease
por: Stefan Schreiber, et al.
Publicado: (2024)

Disease severity in moderate‐to‐severe plaque psoriasis: Results from the Belgian REDISCOVER study
por: Tom Hillary, et al.
Publicado: (2024)

Deucravacitinib in plaque psoriasis: Four‐year safety and efficacy results from the Phase 3 POETYK PSO‐1, PSO‐2 and long‐term extension trials
por: April W. Armstrong, et al.
Publicado: (2025)

Systemic exposure and bioavailability of delgocitinib cream in adults with moderate to severe Chronic Hand Eczema
por: Diamant Thaçi, et al.
Publicado: (2025)

Effect of biologic use on the development of psoriatic arthritis: A population‐based study
por: Kathleen L. Miao, et al.
Publicado: (2025)

Rapid response of nail psoriasis to secukinumab in patients with moderate to severe psoriasis after 12 weeks of treatment with a total of 24 weeks of follow‐up
por: Gang Min Go, et al.
Publicado: (2024)

Deucravacitinib in Japanese patients with plaque, generalized pustular, or erythrodermic psoriasis: Patient‐reported outcomes in the POETYK PSO‐4 study
por: Yayoi Tada, et al.
Publicado: (2024)

Tofacitinib efficacy, patient‐reported outcomes and safety in patients with psoriasis and a medical history of psoriatic arthritis: Pooled analysis of two Phase III studies
por: H. Bachelez, et al.
Publicado: (2024)

A comparison of the safety and efficacy of tapinarof and roflumilast topical therapies in the management of mild‐to‐moderate plaque psoriasis
por: Hira Ghani, et al.
Publicado: (2024)

Ixekizumab optimization in moderate‐to‐severe plaque psoriasis in real clinical practice: a retrospective multicenter study
por: Joan Ceravalls, et al.
Publicado: (2026)

Treatment adjustment in biologic therapies for moderate‐to‐severe plaque psoriasis: a German retrospective chart review (TABU)
por: Natalia Kirsten, et al.
Publicado: (2024)

Secular trends in biologic prescribing for psoriasis and psoriatic arthritis, 2014–2024
por: Mahum Mirza, et al.
Publicado: (2025)

Shedding pounds, easing plaques: Weight management in psoriasis
por: Dimitra Koumaki, et al.
Publicado: (2026)

Real‐world data on the effectiveness of brodalumab in patients with moderate‐to severe plaque psoriasis in the Greek clinical setting (the BrIDGE study)
por: Dimitrios Rigopoulos, et al.
Publicado: (2024)

Risk of peripheral neuropathy in patients with psoriasis and psoriatic arthritis. A prospective cohort study
por: Pietro E. Doneddu, et al.
Publicado: (2024)

RETRACTED: Mendelian randomization analysis of psoriasis and psoriatic arthritis associated with risks of ulcerative colitis
por: Jing Pan, et al.
Publicado: (2024)

Biologic therapies and psoriatic arthritis risk in psoriasis: A systematic review and meta‐analysis
por: Li Yang, et al.
Publicado: (2026)

Anti‐IL‐23 therapy for the treatment of moderate‐to‐severe inverse psoriasis: A 52‐week multicenter study
por: Joan Ceravalls, et al.
Publicado: (2024)

Successful treatment with granulocyte and monocyte adsorption apheresis for plaque‐type skin lesions in patients with psoriatic arthritis
por: Mariko Seishima, et al.
Publicado: (2024)

La economía feminista y los conceptos de valor, eficiencia, escasez, egoísmo y competencia: implicaciones para la educación
por: Myra H. Strober
Publicado: (2001)

Applying Active Learning Methods to the Design of Library Instruction for a Freshman Seminar.
por: Dabbour, Katherine Strober
Publicado: (1997)

Helicobacter pylori infection in psoriatic patients and its relation to psoriasis severity: Cross Sectional Study
por: Soheir Abdel‐Hamid, et al.
Publicado: (2024)

Bimekizumab efficacy and safety in Korean patients with moderate to severe plaque psoriasis: A phase 3, randomized, placebo‐controlled, double‐blinded study
por: Sang Woong Youn, et al.
Publicado: (2024)

Modeling pulsed dye laser treatment of psoriatic plaques by combining numerical methods and image‐derived lesion morphologies
por: Leah S. Wilk, et al.
Publicado: (2024)

Transcriptomic meta‐analysis identifies core molecular pathways in plaque psoriasis
por: Teresa Torres‐Moral, et al.
Publicado: (2026)

Efficacy and safety of topical rosuvastatin & melatonin vs. placebo in patients with mild to moderate plaque psoriasis: A preliminary randomized double‐blinded clinical trial
por: Farhad Mohammadi, et al.
Publicado: (2024)

Successful treatment with guselkumab of anti‐p200 pemphigoid associated with plaque psoriasis
por: Shohei Kitayama, et al.
Publicado: (2024)

Management of IL ‐17 inhibitors‐induced paradoxical eczema in patients with plaque psoriasis
por: Paolo Gisondi, et al.
Publicado: (2025)

Development and evaluation of an online training tool to aid in the diagnosis of chronic plaque psoriasis
por: Maha Abo‐Tabik, et al.
Publicado: (2024)

Dermal lipomatous metaplasia in chronic plaque psoriasis: A clinicopathological case report
por: Marcelo Pacheco Silva, et al.
Publicado: (2026)

Tissue‐resident memory T cells in a psoriatic lesion on a scar: comparison of a continuous lesion of psoriasis, psoriasis with a scar, and non‐lesional skin
por: Masato Ishikawa, et al.
Publicado: (2024)